Serum Heme Oxygenase-1 Measurement is Useful for Evaluating Disease Activity and Outcomes in Patients with Acute Respiratory Distress Syndrome and Acute Exacerbation of Interstitial Lung Disease
Overview
Authors
Affiliations
Background: Oxidative stress plays an important role in acute lung injury, which is associated with the development and progression of acute respiratory failure. Here, we investigated whether the degree of oxidative stress as indicated by serum heme oxygenase-1 (HO-1) is clinically useful for predicting prognosis among the patients with acute respiratory distress syndrome (ARDS) and acute exacerbation of interstitial lung disease (AE-ILD).
Methods: Serum HO-1 levels of newly diagnosed or untreated ARDS and AE-ILD patients were measured at diagnosis. Relationships between serum HO-1 and other clinical parameters and 1 and 3-month mortality were evaluated.
Results: Fifty-five patients including 22 of ARDS and 33 of AE-ILD were assessed. Serum HO-1 level at diagnosis was significantly higher in ARDS patients than AE-ILD patients (87.8 ± 60.0 ng/mL vs. 52.5 ± 36.3 ng/mL, P < 0.001). Serum HO-1 correlated with serum total bilirubin (R = 0.454, P < 0.001) and serum LDH (R = 0.500, P < 0.001). In both patients with ARDS and AE-ILDs, serum HO-1 level tended to decrease from diagnosis to 2 weeks after diagnosis, however, did not normalized. Composite parameters including serum HO-1, age, sex, and partial pressure of oxygen in arterial blood/fraction of inspired oxygen (P/F) ratio for prediction of 3-month mortality showed a higher AUC (ARDS: 0.925, AE-ILDs: 0.892) than did AUCs of a single predictor or combination of two or three predictors.
Conclusion: Oxidative stress assessed by serum HO-1 is persistently high among enrolled patients for 2 weeks after diagnosis. Also, serum HO-1 levels at the diagnosis combined with age, sex, and P/F ratio could be clinically useful for predicting 3-month mortality in both ARDS and AE-ILD patients.
Yue L, Yan Y Int J Chron Obstruct Pulmon Dis. 2025; 20:373-388.
PMID: 39991071 PMC: 11846517. DOI: 10.2147/COPD.S491687.
Voutaz A, Bonnemain J, Ltaief Z, Manuel O, Liaudet L Crit Care. 2024; 28(1):318.
PMID: 39334414 PMC: 11429746. DOI: 10.1186/s13054-024-05087-8.
Heme oxygenase-1 as an important predictor of the severity of COVID-19.
Hara Y, Tsukiji J, Yabe A, Onishi Y, Hirose H, Yamamoto M PLoS One. 2022; 17(8):e0273500.
PMID: 36001619 PMC: 9401165. DOI: 10.1371/journal.pone.0273500.
Kata Y, Hara Y, Tagami Y, Yabe A, Murohashi K, Nagasawa R Sci Rep. 2022; 12(1):12935.
PMID: 35902685 PMC: 9334264. DOI: 10.1038/s41598-022-17290-0.
Ryter S Antioxidants (Basel). 2022; 11(3).
PMID: 35326205 PMC: 8944973. DOI: 10.3390/antiox11030555.